The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world patterns of hyperlipidemia and cardiometabolic toxicity in patients with ALK-fusion– positive NSCLC treated with lorlatinib.
 
Koosha Paydary
Honoraria - MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Bayer; Cardinal Health; Catalyst Pharmaceuticals; Partner Therapeutics
 
Tim Moriarty
No Relationships to Disclose
 
Andrea St Laurent
No Relationships to Disclose
 
Tochukwu Okwuosa
No Relationships to Disclose
 
Jeffrey Borgia
Employment - Rush University
Consulting or Advisory Role - Rational Vaccines
Research Funding - Abbott Diagnostics; Asima health; Tempus
 
Alexis Koon
No Relationships to Disclose
 
Salaheldin Abusin
No Relationships to Disclose
 
Marta Batus
No Relationships to Disclose
 
Helen Ross
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; IDEOlogy Health
Research Funding - Roche (Inst)
 
Marina Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; IO Biotech; Janssen; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Novocure; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Mary Fidler
Honoraria - Daiichi Sankyo/Astra Zeneca; EMD Serono
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Caris Life Sciences; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merus; Novocure; Nuvation Bio; Regeneron
Speakers' Bureau - EMD Serono
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Gilead Sciences (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono